| CAS | 1428135-29-8 |
| Sequence | H-Lys-Asp-Asn-Ile-Lys-His-Val-Pro-Gly-Gly-Gly-Ser-OH |
| Sequence Single | KDNIKHVPGGGS |
| Molecular Formula | C51H85N17O17 |
| Molecular Weight | 1208.32 |
| Synonyms | Microtubule-Associated Protein Tau (610-621) (human) |
| Technology | Synthetic |
| Storage | -20°C, avoid light, cool and dry place |
| Application | Alzheimer’s Disease|Tau Peptides |
| Description | Tau Peptide (294-305) (human), conjugated to KLH via an N-terminal cysteine was tested as anti-tau vaccine. Tau Peptide (294-305) (human) might prevent formation of the beta/beta-helix structure of protofilaments involving residues 306-378. |
| References | 1. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition. B.Riteau et al., Int. Immunol., 13, 193 (2001) 2. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. E. Kontsekova et al., Alzheimers Res. Ther., 6, 44 (2014) |
Tau Peptide (294-305) (human)
CAS No.: 1428135-29-8
Tau Peptide (294-305) (human), conjugated to KLH via an N-terminal cysteine was tested as anti-tau vaccine. Tau Peptide
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.